ARCT-810 Dosing Begun in Phase 1b Trial for OTC Deficiency
Arcaion / Pixabay

ARCT-810 Dosing Begun in Phase 1b Trial for OTC Deficiency

In early December 2020, mRNA medicines company Arcturus Therapeutics Holdings Inc. ("Arcturus") announced that the company begun dosing participants within its Phase 1b clinical trial. Within the trial, researchers will…

Continue Reading ARCT-810 Dosing Begun in Phase 1b Trial for OTC Deficiency
An Ornithine Transcarbamylase Deficiency Treatment Has Been Approved for Clinical Trials
Pixabay

An Ornithine Transcarbamylase Deficiency Treatment Has Been Approved for Clinical Trials

Ornithine transcarbamylase (OTC) deficiency is a disorder that can cause comas, seizures, and death, making it necessary for those affected to seek treatment. Arcturus Therapeutics aims to give those with…

Continue Reading An Ornithine Transcarbamylase Deficiency Treatment Has Been Approved for Clinical Trials

Gene Therapy: The New Frontier for Cancer

  Gene therapy is the treatment of disease by way of the transfer of genetic material into cells. According to a recent article in Labiotech, an EU publication, gene therapy…

Continue Reading Gene Therapy: The New Frontier for Cancer
New Updates From Translate Bio in Drug Development for Cystic Fibrosis and OTC Deficiency
geralt / Pixabay

New Updates From Translate Bio in Drug Development for Cystic Fibrosis and OTC Deficiency

According to a story from globenewswire.com, the messenger RNA therapeutics company Translate Bio recently released the latest updates in regards to two of its leading product candidates for the treatment…

Continue Reading New Updates From Translate Bio in Drug Development for Cystic Fibrosis and OTC Deficiency